These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30615403)

  • 41. JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.
    Sarid N; Eshel R; Rahamim E; Carmiel M; Kirgner I; Shpringer M; Trestman S; Marilus R; Perry C; Polliack A; Naparstek E; Herishanu Y
    Isr Med Assoc J; 2013 Nov; 15(11):698-700. PubMed ID: 24511651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
    Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
    Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
    Maslah N; Verger E; Schlageter MH; Miclea JM; Kiladjian JJ; Giraudier S; Chomienne C; Cassinat B
    Ann Hematol; 2019 Jan; 98(1):111-118. PubMed ID: 30259120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2.
    Shepard GC; Lawson HL; Hawkins GA; Owen J
    Int J Lab Hematol; 2011 Jun; 33(3):267-71. PubMed ID: 21118387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A novel modi cation of real-time AS-qPCR by using locked nucleic acid-modified oligonucleotide probe as wild type allele amplification blockers for quantitative detection of the JAK2 V617F mutation].
    Shao DH; Liang GW; He ML; Cao QY
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):421-5. PubMed ID: 23688754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms.
    Minnucci G; Amicarelli G; Salmoiraghi S; Spinelli O; Guinea Montalvo ML; Giussani U; Adlerstein D; Rambaldi A
    Haematologica; 2012 Sep; 97(9):1394-400. PubMed ID: 22315499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients].
    Hu GY; Deng MY; Zhang GS; Luo YY; Zhu JF
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):394-8. PubMed ID: 19951533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. JAK2 V617F mutation detection: laboratory comparison of two kits using RFLP and qPCR.
    Shammaa D; Bazarbachi A; Halas H; Greige L; Mahfouz R
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):13-5. PubMed ID: 19877761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The quantitative testing of V617F mutation in gen JAK2 using pyrosequencing technique].
    Dunaeva EA; Mironov KO; Dribnokhodova TE; Subbotina EE; Bashmakova ; Ol'hovskiĭ IA; Shipulin GA
    Klin Lab Diagn; 2014 Nov; 59(11):60-3. PubMed ID: 25850251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
    Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
    Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
    Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
    Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
    Steensma DP
    J Mol Diagn; 2006 Sep; 8(4):397-411; quiz 526. PubMed ID: 16931578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. JAK2 V617F "indeterminate" results by MutaScreen can be easily resolved using MutaQuant kits.
    Hoteit RM; Shammaa DM; Mahfouz RA
    Genet Test Mol Biomarkers; 2012 Feb; 16(2):146-9. PubMed ID: 21933004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
    Mercier F; Monczak Y; François M; Prchal J; Galipeau J
    Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.
    Mahfouz RA; Hoteit R; Salem Z; Bazarbachi A; Mugharbel A; Farhat F; Ziyadeh A; Ibrahim A; Taher A
    Genet Test Mol Biomarkers; 2011 Apr; 15(4):263-5. PubMed ID: 21198321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.